Exciting News from Enantis!
Our brilliant PhD candidate, Gabin de La Bourdonnaye, has developed a game-changing thermostable FGF21 growth factor 🌡️, soon to join Enantis‘ portfolio. Check out the paper here: https://lnkd.in/eFfzBBT8

This novel growth factor has the potential to revolutionize metabolic disease treatment— think obesity, dyslipidemia, and insulin intolerance. Engineered for thermostability, it shows improved pharmacokinetics, allowing for lower dosage and reduced administration frequency, minimizing side effects.

Interested in exploring the potential of thermostable FGF21? Reach out, and we’ll provide more info.

Let’s shape the future of growth factors together! 🚀